NEWS: 公告在东京证券交易所JASDAQ标准市场新上市

市场调查报告书

血浆替换疗法的全球市场

Therapeutic Plasma Exchange

出版商 Global Industry Analysts, Inc. 商品编码 997570
出版日期 内容资讯 英文 188 Pages
商品交期: 最快1-2个工作天内
价格
血浆替换疗法的全球市场 Therapeutic Plasma Exchange
出版日期: 2021年04月01日内容资讯: 英文 188 Pages
简介

全球血浆替换疗法的市场规模,预计在分析期间(2020年~2027年)将以5.9%的年复合成长率增长,从2020年的12亿美元,到2027年达到18亿美元。

本报告所分析的市场区隔之一的神经病变部门,在分析期间中预计将以6.7%的年复合成长率增长,达到6亿2,200万美元。

本报告提供全球血浆替换疗法市场的相关调查,提供市场占有率,Covid-19的影响,趋势和成长要素,各地区的市场分析,竞争情形,主要企业的简介等资讯。

调查对象企业范例

  • Asahi Kasei Medical Co., Ltd.
  • B. Braun Melsungen AG
  • Baxter International, Inc.
  • Fenwal, Inc.
  • Fresenius SE & Co. KGaA
  • Haemonetics Corporation
  • HemaCare Corporation
  • Kawasumi Laboratories, Inc.
  • Terumo BCT, Inc.

目录

I. 调查手法

II. 摘要整理

  • 市场概要
    • 影响者市场洞察
    • 全球市场的轨迹
    • Covid-19的影响与即将到来的全球景气衰退
  • 主要企业
  • 趋势与推动要素
  • 全球市场预测

III. 市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 其他欧洲
  • 亚太地区
  • 其他地区

IV. 竞争

  • 企业简介:47公司

本网页内容可能与最新版本有所差异。详细情况请与我们联系。

目录
Product Code: MCP15189

Abstract:

Global Therapeutic Plasma Exchange Market to Reach $1.8 Billion by 2027

Amid the COVID-19 crisis, the global market for Therapeutic Plasma Exchange estimated at US$1.2 Billion in the year 2020, is projected to reach a revised size of US$1.8 Billion by 2027, growing at a CAGR of 5.9% over the analysis period 2020-2027. Neurological Disorders, one of the segments analyzed in the report, is projected to record a 6.7% CAGR and reach US$622 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Renal Disorders segment is readjusted to a revised 5.2% CAGR for the next 7-year period.

The U.S. Market is Estimated at $347.6 Million, While China is Forecast to Grow at 5.5% CAGR

The Therapeutic Plasma Exchange market in the U.S. is estimated at US$347.6 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$308.9 Million by the year 2027 trailing a CAGR of 5.5% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.7% and 4.7% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.8% CAGR.

Hematology Disorders Segment to Record 6.1% CAGR

In the global Hematology Disorders segment, USA, Canada, Japan, China and Europe will drive the 6.1% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$180.5 Million in the year 2020 will reach a projected size of US$274 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$201.9 Million by the year 2027.

Select Competitors (Total 47 Featured) -

  • Asahi Kasei Medical Co., Ltd.
  • B. Braun Melsungen AG
  • Baxter International, Inc.
  • Fenwal, Inc.
  • Fresenius SE & Co. KGaA
  • Haemonetics Corporation
  • HemaCare Corporation
  • Kawasumi Laboratories, Inc.
  • Terumo BCT, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for Therapeutic Plasma Exchange by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 2: World Historic Review for Therapeutic Plasma Exchange by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 3: World 15-Year Perspective for Therapeutic Plasma Exchange by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
    • TABLE 4: World Current & Future Analysis for Neurological Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 5: World Historic Review for Neurological Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 6: World 15-Year Perspective for Neurological Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 7: World Current & Future Analysis for Renal Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 8: World Historic Review for Renal Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 9: World 15-Year Perspective for Renal Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 10: World Current & Future Analysis for Hematology Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 11: World Historic Review for Hematology Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 12: World 15-Year Perspective for Hematology Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 13: World Current & Future Analysis for Metabolic Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 14: World Historic Review for Metabolic Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 15: World 15-Year Perspective for Metabolic Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 16: World Current & Future Analysis for Other Disease Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 17: World Historic Review for Other Disease Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 18: World 15-Year Perspective for Other Disease Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 19: World Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 20: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 21: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 22: World Current & Future Analysis for Specialty Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 23: World Historic Review for Specialty Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 24: World 15-Year Perspective for Specialty Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 25: World Current & Future Analysis for Ambulatory Surgical Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 26: World Historic Review for Ambulatory Surgical Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 27: World 15-Year Perspective for Ambulatory Surgical Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • TABLE 28: USA Current & Future Analysis for Therapeutic Plasma Exchange by Disease Indication - Neurological Disorders, Renal Disorders, Hematology Disorders, Metabolic Disorders and Other Disease Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 29: USA Historic Review for Therapeutic Plasma Exchange by Disease Indication - Neurological Disorders, Renal Disorders, Hematology Disorders, Metabolic Disorders and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 30: USA 15-Year Perspective for Therapeutic Plasma Exchange by Disease Indication - Percentage Breakdown of Value Sales for Neurological Disorders, Renal Disorders, Hematology Disorders, Metabolic Disorders and Other Disease Indications for the Years 2012, 2020 & 2027
    • TABLE 31: USA Current & Future Analysis for Therapeutic Plasma Exchange by End-Use - Hospitals, Specialty Clinics and Ambulatory Surgical Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 32: USA Historic Review for Therapeutic Plasma Exchange by End-Use - Hospitals, Specialty Clinics and Ambulatory Surgical Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 33: USA 15-Year Perspective for Therapeutic Plasma Exchange by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Ambulatory Surgical Centers for the Years 2012, 2020 & 2027
  • CANADA
    • TABLE 34: Canada Current & Future Analysis for Therapeutic Plasma Exchange by Disease Indication - Neurological Disorders, Renal Disorders, Hematology Disorders, Metabolic Disorders and Other Disease Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 35: Canada Historic Review for Therapeutic Plasma Exchange by Disease Indication - Neurological Disorders, Renal Disorders, Hematology Disorders, Metabolic Disorders and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 36: Canada 15-Year Perspective for Therapeutic Plasma Exchange by Disease Indication - Percentage Breakdown of Value Sales for Neurological Disorders, Renal Disorders, Hematology Disorders, Metabolic Disorders and Other Disease Indications for the Years 2012, 2020 & 2027
    • TABLE 37: Canada Current & Future Analysis for Therapeutic Plasma Exchange by End-Use - Hospitals, Specialty Clinics and Ambulatory Surgical Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 38: Canada Historic Review for Therapeutic Plasma Exchange by End-Use - Hospitals, Specialty Clinics and Ambulatory Surgical Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 39: Canada 15-Year Perspective for Therapeutic Plasma Exchange by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Ambulatory Surgical Centers for the Years 2012, 2020 & 2027
  • JAPAN
    • TABLE 40: Japan Current & Future Analysis for Therapeutic Plasma Exchange by Disease Indication - Neurological Disorders, Renal Disorders, Hematology Disorders, Metabolic Disorders and Other Disease Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 41: Japan Historic Review for Therapeutic Plasma Exchange by Disease Indication - Neurological Disorders, Renal Disorders, Hematology Disorders, Metabolic Disorders and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 42: Japan 15-Year Perspective for Therapeutic Plasma Exchange by Disease Indication - Percentage Breakdown of Value Sales for Neurological Disorders, Renal Disorders, Hematology Disorders, Metabolic Disorders and Other Disease Indications for the Years 2012, 2020 & 2027
    • TABLE 43: Japan Current & Future Analysis for Therapeutic Plasma Exchange by End-Use - Hospitals, Specialty Clinics and Ambulatory Surgical Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 44: Japan Historic Review for Therapeutic Plasma Exchange by End-Use - Hospitals, Specialty Clinics and Ambulatory Surgical Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 45: Japan 15-Year Perspective for Therapeutic Plasma Exchange by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Ambulatory Surgical Centers for the Years 2012, 2020 & 2027
  • CHINA
    • TABLE 46: China Current & Future Analysis for Therapeutic Plasma Exchange by Disease Indication - Neurological Disorders, Renal Disorders, Hematology Disorders, Metabolic Disorders and Other Disease Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 47: China Historic Review for Therapeutic Plasma Exchange by Disease Indication - Neurological Disorders, Renal Disorders, Hematology Disorders, Metabolic Disorders and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 48: China 15-Year Perspective for Therapeutic Plasma Exchange by Disease Indication - Percentage Breakdown of Value Sales for Neurological Disorders, Renal Disorders, Hematology Disorders, Metabolic Disorders and Other Disease Indications for the Years 2012, 2020 & 2027
    • TABLE 49: China Current & Future Analysis for Therapeutic Plasma Exchange by End-Use - Hospitals, Specialty Clinics and Ambulatory Surgical Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 50: China Historic Review for Therapeutic Plasma Exchange by End-Use - Hospitals, Specialty Clinics and Ambulatory Surgical Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 51: China 15-Year Perspective for Therapeutic Plasma Exchange by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Ambulatory Surgical Centers for the Years 2012, 2020 & 2027
  • EUROPE
    • TABLE 52: Europe Current & Future Analysis for Therapeutic Plasma Exchange by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 53: Europe Historic Review for Therapeutic Plasma Exchange by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 54: Europe 15-Year Perspective for Therapeutic Plasma Exchange by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
    • TABLE 55: Europe Current & Future Analysis for Therapeutic Plasma Exchange by Disease Indication - Neurological Disorders, Renal Disorders, Hematology Disorders, Metabolic Disorders and Other Disease Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 56: Europe Historic Review for Therapeutic Plasma Exchange by Disease Indication - Neurological Disorders, Renal Disorders, Hematology Disorders, Metabolic Disorders and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 57: Europe 15-Year Perspective for Therapeutic Plasma Exchange by Disease Indication - Percentage Breakdown of Value Sales for Neurological Disorders, Renal Disorders, Hematology Disorders, Metabolic Disorders and Other Disease Indications for the Years 2012, 2020 & 2027
    • TABLE 58: Europe Current & Future Analysis for Therapeutic Plasma Exchange by End-Use - Hospitals, Specialty Clinics and Ambulatory Surgical Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 59: Europe Historic Review for Therapeutic Plasma Exchange by End-Use - Hospitals, Specialty Clinics and Ambulatory Surgical Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 60: Europe 15-Year Perspective for Therapeutic Plasma Exchange by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Ambulatory Surgical Centers for the Years 2012, 2020 & 2027
  • FRANCE
    • TABLE 61: France Current & Future Analysis for Therapeutic Plasma Exchange by Disease Indication - Neurological Disorders, Renal Disorders, Hematology Disorders, Metabolic Disorders and Other Disease Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 62: France Historic Review for Therapeutic Plasma Exchange by Disease Indication - Neurological Disorders, Renal Disorders, Hematology Disorders, Metabolic Disorders and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 63: France 15-Year Perspective for Therapeutic Plasma Exchange by Disease Indication - Percentage Breakdown of Value Sales for Neurological Disorders, Renal Disorders, Hematology Disorders, Metabolic Disorders and Other Disease Indications for the Years 2012, 2020 & 2027
    • TABLE 64: France Current & Future Analysis for Therapeutic Plasma Exchange by End-Use - Hospitals, Specialty Clinics and Ambulatory Surgical Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 65: France Historic Review for Therapeutic Plasma Exchange by End-Use - Hospitals, Specialty Clinics and Ambulatory Surgical Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 66: France 15-Year Perspective for Therapeutic Plasma Exchange by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Ambulatory Surgical Centers for the Years 2012, 2020 & 2027
  • GERMANY
    • TABLE 67: Germany Current & Future Analysis for Therapeutic Plasma Exchange by Disease Indication - Neurological Disorders, Renal Disorders, Hematology Disorders, Metabolic Disorders and Other Disease Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 68: Germany Historic Review for Therapeutic Plasma Exchange by Disease Indication - Neurological Disorders, Renal Disorders, Hematology Disorders, Metabolic Disorders and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 69: Germany 15-Year Perspective for Therapeutic Plasma Exchange by Disease Indication - Percentage Breakdown of Value Sales for Neurological Disorders, Renal Disorders, Hematology Disorders, Metabolic Disorders and Other Disease Indications for the Years 2012, 2020 & 2027
    • TABLE 70: Germany Current & Future Analysis for Therapeutic Plasma Exchange by End-Use - Hospitals, Specialty Clinics and Ambulatory Surgical Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 71: Germany Historic Review for Therapeutic Plasma Exchange by End-Use - Hospitals, Specialty Clinics and Ambulatory Surgical Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 72: Germany 15-Year Perspective for Therapeutic Plasma Exchange by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Ambulatory Surgical Centers for the Years 2012, 2020 & 2027
  • ITALY
    • TABLE 73: Italy Current & Future Analysis for Therapeutic Plasma Exchange by Disease Indication - Neurological Disorders, Renal Disorders, Hematology Disorders, Metabolic Disorders and Other Disease Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 74: Italy Historic Review for Therapeutic Plasma Exchange by Disease Indication - Neurological Disorders, Renal Disorders, Hematology Disorders, Metabolic Disorders and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 75: Italy 15-Year Perspective for Therapeutic Plasma Exchange by Disease Indication - Percentage Breakdown of Value Sales for Neurological Disorders, Renal Disorders, Hematology Disorders, Metabolic Disorders and Other Disease Indications for the Years 2012, 2020 & 2027
    • TABLE 76: Italy Current & Future Analysis for Therapeutic Plasma Exchange by End-Use - Hospitals, Specialty Clinics and Ambulatory Surgical Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 77: Italy Historic Review for Therapeutic Plasma Exchange by End-Use - Hospitals, Specialty Clinics and Ambulatory Surgical Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 78: Italy 15-Year Perspective for Therapeutic Plasma Exchange by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Ambulatory Surgical Centers for the Years 2012, 2020 & 2027
  • UNITED KINGDOM
    • TABLE 79: UK Current & Future Analysis for Therapeutic Plasma Exchange by Disease Indication - Neurological Disorders, Renal Disorders, Hematology Disorders, Metabolic Disorders and Other Disease Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 80: UK Historic Review for Therapeutic Plasma Exchange by Disease Indication - Neurological Disorders, Renal Disorders, Hematology Disorders, Metabolic Disorders and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 81: UK 15-Year Perspective for Therapeutic Plasma Exchange by Disease Indication - Percentage Breakdown of Value Sales for Neurological Disorders, Renal Disorders, Hematology Disorders, Metabolic Disorders and Other Disease Indications for the Years 2012, 2020 & 2027
    • TABLE 82: UK Current & Future Analysis for Therapeutic Plasma Exchange by End-Use - Hospitals, Specialty Clinics and Ambulatory Surgical Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 83: UK Historic Review for Therapeutic Plasma Exchange by End-Use - Hospitals, Specialty Clinics and Ambulatory Surgical Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 84: UK 15-Year Perspective for Therapeutic Plasma Exchange by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Ambulatory Surgical Centers for the Years 2012, 2020 & 2027
  • REST OF EUROPE
    • TABLE 85: Rest of Europe Current & Future Analysis for Therapeutic Plasma Exchange by Disease Indication - Neurological Disorders, Renal Disorders, Hematology Disorders, Metabolic Disorders and Other Disease Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 86: Rest of Europe Historic Review for Therapeutic Plasma Exchange by Disease Indication - Neurological Disorders, Renal Disorders, Hematology Disorders, Metabolic Disorders and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 87: Rest of Europe 15-Year Perspective for Therapeutic Plasma Exchange by Disease Indication - Percentage Breakdown of Value Sales for Neurological Disorders, Renal Disorders, Hematology Disorders, Metabolic Disorders and Other Disease Indications for the Years 2012, 2020 & 2027
    • TABLE 88: Rest of Europe Current & Future Analysis for Therapeutic Plasma Exchange by End-Use - Hospitals, Specialty Clinics and Ambulatory Surgical Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 89: Rest of Europe Historic Review for Therapeutic Plasma Exchange by End-Use - Hospitals, Specialty Clinics and Ambulatory Surgical Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 90: Rest of Europe 15-Year Perspective for Therapeutic Plasma Exchange by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Ambulatory Surgical Centers for the Years 2012, 2020 & 2027
  • ASIA-PACIFIC
    • TABLE 91: Asia-Pacific Current & Future Analysis for Therapeutic Plasma Exchange by Disease Indication - Neurological Disorders, Renal Disorders, Hematology Disorders, Metabolic Disorders and Other Disease Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 92: Asia-Pacific Historic Review for Therapeutic Plasma Exchange by Disease Indication - Neurological Disorders, Renal Disorders, Hematology Disorders, Metabolic Disorders and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 93: Asia-Pacific 15-Year Perspective for Therapeutic Plasma Exchange by Disease Indication - Percentage Breakdown of Value Sales for Neurological Disorders, Renal Disorders, Hematology Disorders, Metabolic Disorders and Other Disease Indications for the Years 2012, 2020 & 2027
    • TABLE 94: Asia-Pacific Current & Future Analysis for Therapeutic Plasma Exchange by End-Use - Hospitals, Specialty Clinics and Ambulatory Surgical Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 95: Asia-Pacific Historic Review for Therapeutic Plasma Exchange by End-Use - Hospitals, Specialty Clinics and Ambulatory Surgical Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 96: Asia-Pacific 15-Year Perspective for Therapeutic Plasma Exchange by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Ambulatory Surgical Centers for the Years 2012, 2020 & 2027
  • REST OF WORLD
    • TABLE 97: Rest of World Current & Future Analysis for Therapeutic Plasma Exchange by Disease Indication - Neurological Disorders, Renal Disorders, Hematology Disorders, Metabolic Disorders and Other Disease Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 98: Rest of World Historic Review for Therapeutic Plasma Exchange by Disease Indication - Neurological Disorders, Renal Disorders, Hematology Disorders, Metabolic Disorders and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 99: Rest of World 15-Year Perspective for Therapeutic Plasma Exchange by Disease Indication - Percentage Breakdown of Value Sales for Neurological Disorders, Renal Disorders, Hematology Disorders, Metabolic Disorders and Other Disease Indications for the Years 2012, 2020 & 2027
    • TABLE 100: Rest of World Current & Future Analysis for Therapeutic Plasma Exchange by End-Use - Hospitals, Specialty Clinics and Ambulatory Surgical Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 101: Rest of World Historic Review for Therapeutic Plasma Exchange by End-Use - Hospitals, Specialty Clinics and Ambulatory Surgical Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 102: Rest of World 15-Year Perspective for Therapeutic Plasma Exchange by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Ambulatory Surgical Centers for the Years 2012, 2020 & 2027

IV. COMPETITION

  • Total Companies Profiled: 47